Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer: a Randomized Phase II Trial
University Health Network, Toronto
75 participants
Jul 8, 2025
INTERVENTIONAL
Conditions
Summary
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).
Eligibility
Inclusion Criteria8
- Age \>18 years
- Able to provide informed consent
- Histologic diagnosis of prostate adenocarcinoma
- Castrate Resistance Prostate Cancer
- Radiographic evidence of \<10 sites of extra-cranial OP metastatic lesions
- Receiving any line of ST for \>3 months
- All sites of OP disease are amenable to and can be safely treated with SBRT
- ECOG performance status 0-3
Exclusion Criteria2
- Evidence of spinal cord compression
- Contraindication to radiotherapy
Interventions
SBRT will be delivered as per institutional standard.
Participants will receive Systemic Therapy. Participants in Arm 1 - SOC may change the Systemic Therapy throughout treatment. Participants in Arm 2 - Experimental will remain on the same Systemic Therapy throughout treatment.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06927635